Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,100.82
(
-0.35%
)
US TECH 100
25,832.40
(
-0.47%
)
Dow Jones
49,348.62
(
-0.20%
)
Brent Oil
91.90
(
-0.81%
)
Bitcoin
76,307.13
(
3.31%
)
News Focus
News Focus
Post# of 257430
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: Praveen post# 148057

Saturday, 09/01/2012 12:07:53 PM

Saturday, September 01, 2012 12:07:53 PM

Post# of 257430

Hasn't it been stuck in pre clin for a long time?

I don't believe so. As stated in #msg-79157547, AZD3293 is the successor BACE inhibitor to AZD3839 upon the Phase 1 results of the latter. Clinicaltrials.gov reports the Phase 1 trial for AZD3839 was complete in November 2011 after a June 2011 start. So, presumably further work had to be done on AZD3293 after those November 2011 results from the first BACE inhibitor to improve upon it.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today